Your browser is no longer supported. Please, upgrade your browser.
Settings
ABBV [NYSE]
AbbVie Inc.
IndexS&P 500 P/E39.08 EPS (ttm)2.71 Insider Own0.10% Shs Outstand1.77B Perf Week0.66%
Market Cap184.39B Forward P/E7.63 EPS next Y13.88 Insider Trans-31.74% Shs Float1.76B Perf Month-3.95%
Income4.55B PEG9.53 EPS next Q2.85 Inst Own69.70% Short Float0.95% Perf Quarter-3.53%
Sales45.80B P/S4.03 EPS this Y-48.50% Inst Trans-0.51% Short Ratio2.27 Perf Half Y19.90%
Book/sh7.39 P/B14.33 EPS next Y11.39% ROA3.40% Target Price122.17 Perf Year28.94%
Cash/sh4.87 P/C21.75 EPS next 5Y4.10% ROE51.10% 52W Range79.11 - 113.41 Perf YTD-1.17%
Dividend5.20 P/FCF20.32 EPS past 5Y-2.80% ROI12.70% 52W High-6.62% Beta0.80
Dividend %4.91% Quick Ratio0.70 Sales past 5Y14.90% Gross Margin66.40% 52W Low33.86% ATR2.07
Employees47000 Current Ratio0.80 Sales Q/Q59.20% Oper. Margin24.80% RSI (14)47.72 Volatility1.29% 1.76%
OptionableYes Debt/Eq6.58 EPS Q/Q-99.40% Profit Margin9.90% Rel Volume1.05 Prev Close108.22
ShortableYes LT Debt/Eq5.93 EarningsApr 30 BMO Payout173.80% Avg Volume7.39M Price105.90
Recom2.00 SMA20-0.27% SMA50-0.46% SMA2006.72% Volume7,747,144 Change-2.14%
Apr-07-21Resumed RBC Capital Mkts Outperform $135
Nov-10-20Resumed Bernstein Outperform $120
Sep-29-20Initiated Berenberg Hold $98
Jun-23-20Upgrade Atlantic Equities Neutral → Overweight $115
Jun-09-20Upgrade Wolfe Research Peer Perform → Outperform
Jun-02-20Upgrade Argus Hold → Buy $115
May-18-20Resumed BofA/Merrill Neutral $95
May-12-20Upgrade JP Morgan Neutral → Overweight $105
May-11-20Resumed Morgan Stanley Overweight $95
Apr-20-20Upgrade RBC Capital Mkts Sector Perform → Outperform $79 → $93
Mar-23-20Downgrade Societe Generale Buy → Hold
Feb-27-20Initiated Barclays Equal Weight $97
Feb-06-20Initiated Mizuho Buy
Jan-07-20Initiated RBC Capital Mkts Sector Perform $86
Dec-26-19Reiterated Cowen Outperform $90 → $98
Sep-26-19Upgrade Citigroup Neutral → Buy $87 → $90
Aug-20-19Upgrade Piper Jaffray Neutral → Overweight $80
Jun-27-19Upgrade Wolfe Research Underperform → Peer Perform
Jun-26-19Upgrade SVB Leerink Mkt Perform → Outperform $88
May-28-19Initiated Goldman Neutral
Apr-14-21 10:54AM  
07:01AM  
Apr-13-21 06:46PM  
05:45PM  
09:15AM  
08:02AM  
05:12AM  
Apr-12-21 12:00PM  
11:45AM  
11:30AM  
Apr-11-21 06:30AM  
06:01AM  
Apr-10-21 06:01AM  
Apr-09-21 09:51AM  
07:24AM  
01:01AM  
Apr-08-21 08:13AM  
07:15AM  
Apr-07-21 07:53PM  
10:14AM  
09:10AM  
09:00AM  
08:00AM  
Apr-06-21 07:23AM  
Apr-05-21 08:17AM  
Apr-04-21 06:01AM  
Apr-03-21 07:25AM  
Apr-02-21 05:18PM  
Apr-01-21 08:45AM  
08:31AM  
Mar-31-21 11:59AM  
08:00AM  
06:04AM  
Mar-30-21 08:00AM  
Mar-29-21 05:45PM  
04:00PM  
Mar-28-21 06:08AM  
Mar-26-21 11:45AM  
Mar-25-21 07:45AM  
Mar-24-21 06:25AM  
Mar-23-21 05:45PM  
Mar-22-21 01:17PM  
06:06AM  
Mar-21-21 11:34PM  
06:01AM  
Mar-20-21 01:35PM  
Mar-19-21 05:42PM  
12:00AM  
Mar-18-21 07:26PM  
03:07PM  
09:12AM  
07:52AM  
Mar-17-21 04:16PM  
10:54AM  
09:36AM  
09:05AM  
08:45AM  
08:22AM  
06:20AM  
06:04AM  
Mar-16-21 12:42PM  
12:13PM  
06:01AM  
05:57AM  
03:40AM  
Mar-15-21 05:45PM  
04:50PM  
06:53AM  
Mar-14-21 06:01AM  
Mar-12-21 07:36PM  
12:32PM  
Mar-11-21 07:10AM  
06:25AM  
Mar-10-21 01:28PM  
11:45AM  
Mar-09-21 06:09AM  
06:06AM  
Mar-07-21 03:28PM  
05:51AM  
Mar-06-21 01:04AM  
Mar-05-21 11:30AM  
08:17AM  
Mar-04-21 11:00AM  
Mar-02-21 11:18AM  
06:01AM  
04:41AM  
Mar-01-21 01:33PM  
05:34AM  
Feb-26-21 10:06AM  
Feb-25-21 08:08AM  
08:00AM  
Feb-24-21 07:14PM  
11:09AM  
09:31AM  
Feb-23-21 08:30AM  
07:37AM  
06:04AM  
Feb-22-21 04:38PM  
12:29PM  
08:45AM  
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GONZALEZ RICHARD AChairman of the Board and CEOMar 02Option Exercise54.86170,1139,332,399546,710Mar 02 08:27 PM
RICHMOND TIMOTHY J.EVP, Chief HR OfficerMar 01Sale108.5919,5142,119,0410Mar 02 08:31 PM
Sorg Elaine K.SVP, US Commercial OperationsMar 01Sale108.618,440916,64217,595Mar 02 08:30 PM
GONZALEZ RICHARD AChairman of the Board and CEOMar 01Sale108.61170,11318,476,204376,597Mar 02 08:27 PM
Stewart Jeffrey RyanSVP, US Commercial OperationsMar 01Sale108.5913,7731,495,57650,969Mar 02 08:26 PM
Sorg Elaine K.SVP, US Commercial OperationsFeb 22Option Exercise89.7820,1951,813,05252,946Feb 24 06:28 PM
Sorg Elaine K.SVP, US Commercial OperationsFeb 22Sale104.7220,1952,114,73232,751Feb 24 06:28 PM
Stewart Jeffrey RyanEVP, Commercial OperationsDec 29Option Exercise51.4225,2901,300,41276,259Dec 31 01:15 PM
Stewart Jeffrey RyanEVP, Commercial OperationsDec 29Sale105.0025,2902,655,45050,969Dec 31 01:15 PM
RICHMOND TIMOTHY J.EVP, Chief HR OfficerNov 27Option Exercise51.4251,9902,673,32651,990Dec 01 05:22 PM
RICHMOND TIMOTHY J.EVP, Chief HR OfficerNov 27Sale105.0051,9905,458,9500Dec 01 05:22 PM
Gosebruch Henry OEVP, Chief Strategy OfficerNov 20Sale99.3840,0003,975,04620,006Nov 24 05:34 PM
ALBAN CARLOSVice ChairmanNov 16Option Exercise35.88115,8304,155,980230,729Nov 18 05:04 PM
ALBAN CARLOSVice ChairmanNov 16Sale100.00115,83011,583,000114,899Nov 18 05:04 PM
GONZALEZ RICHARD AChairman of the Board and CEONov 12Option Exercise57.12194,15411,089,858512,796Nov 12 05:54 PM
GONZALEZ RICHARD AChairman of the Board and CEONov 12Sale97.10194,15418,851,790318,642Nov 12 05:54 PM
SALEKI-GERHARDT AZITAEVP, OperationsNov 10Sale98.0017,4261,707,74896,441Nov 12 05:56 PM
GONZALEZ RICHARD AChairman of the Board and CEONov 09Sale95.7437,4503,585,463318,642Nov 12 05:54 PM
SALEKI-GERHARDT AZITAEVP, OperationsNov 04Sale93.614,800449,328109,067Nov 06 04:29 PM
SEVERINO MICHAELVice ChairmanNov 04Sale93.6190,6798,488,46167,281Nov 06 04:29 PM
ALBAN CARLOSVice ChairmanJul 07Sale100.0053,3255,332,555114,899Jul 08 09:19 PM
Stewart Jeffrey RyanSVP, US Commercial OperationsMay 12Sale90.0023,0242,072,21152,760May 12 05:44 PM
RICHMOND TIMOTHY J.EVP, Chief HR OfficerMay 05Sale85.0019,4451,652,8250May 07 05:01 PM